We are live on ! Find out more
CAC

Cowen and Company Portfolio holdings

AUM $2.97B
1-Year Est. Return 105.26%
This Fund
S&P 500
This Quarter Est. Return
+5.02%
1 Year Est. Return
+105.26%
3 Year Est. Return
+120.05%
5 Year Est. Return
+670.56%
10 Year Est. Return
AUM
$1.05B
AUM Growth
+$9.85M
Cap. Flow
+$95.1M
Cap. Flow %
9.1%
Top 10 Hldgs %
50%
Holding
874
New
223
Increased
214
Reduced
73
Closed
220

Sector Composition

Rank Sector Weight
1 Healthcare 34.11%
2 Financials 8.03%
3 Materials 6.97%
4 Technology 3.58%
5 Industrials 3.34%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
KAHC
151
DELISTED
KKR Acquisition Holdings I Corp.
KAHC
$246K 0.02%
25,000
VGASW icon
152
Verde Clean Fuels Warrant
VGASW
$761K
$244K 0.02%
1,341,549
+1,038,680
+343% +$150K
PCT icon
153
PureCycle Technologies
PCT
$1.46B
$243K 0.02%
30,097
+2,911
+11% +$24.9K
XLK icon
154
State Street Technology Select Sector SPDR ETF
XLK
$122B
$238K 0.02%
+4,000
New +$273K
QQQ icon
155
Invesco QQQ Trust
QQQ
$479B
$236K 0.02%
+30,000
New +$9.05M
BAC icon
156
Bank of America
BAC
$447B
$235K 0.02%
11,425
+3,025
+36% +$101K
DMYS.WS
157
DELISTED
dMY Technology Group, Inc. VI Redeemable Warrants, each whole warrant exercisable for one share of Class A common stock at an exercise price of $11.50 per share
DMYS.WS
$234K 0.02%
491,083
+76,629
+18% +$22.3K
ALGN icon
158
Align Technology
ALGN
$12.5B
$228K 0.02%
+1,103
New +$284K
HOLX
159
DELISTED
Hologic
HOLX
$228K 0.02%
+3,528
New +$244K
CPUH.U
160
DELISTED
Compute Health Acquisition Corp. Units, each consisting of one share of Class A common stock and one-quarter of one redeemable warrant
CPUH.U
$225K 0.02%
+22,800
New +$225K
HIX
161
Western Asset High Income Fund II
HIX
$355M
$219K 0.02%
50,140
-3,026
-6% -$16K
CTLT
162
DELISTED
CATALENT, INC.
CTLT
$219K 0.02%
+3,021
New +$300K
HMCOW
163
DELISTED
HumanCo Acquisition Corp. Warrant
HMCOW
$207K 0.02%
1,885,114
+78,808
+4% +$7.63K
SOC.WS
164
DELISTED
Sable Offshore Corp. Warrants, each whole warrant exercisable for one share of Common Stock at an exercise price of $11.50
SOC.WS
$205K 0.02%
1,463,770
+1,122,158
+328% +$221K
DGX icon
165
Quest Diagnostics
DGX
$26.2B
$204K 0.02%
+1,659
New +$218K
COR icon
166
Cencora
COR
$62B
$202K 0.02%
+1,489
New +$214K
RVTY icon
167
Revvity
RVTY
$12.9B
$201K 0.02%
+1,674
New +$236K
IPOF
168
DELISTED
Social Capital Hedosophia Holdings Corp. VI
IPOF
$200K 0.02%
20,000
ARYD
169
DELISTED
ARYA Sciences Acquisition Corp IV Class A Odinary Shares
ARYD
$194K 0.02%
19,600
BWACW
170
DELISTED
BETTER WORLD ACQUISITION CORP. Warrants
BWACW
$193K 0.02%
2,274,637
+561,188
+33% +$40.2K
GAPA
171
DELISTED
G&P Acquisition Corp.
GAPA
$189K 0.02%
+18,951
New +$189K
FLNA
172
Filana Therapeutics
FLNA
$48.2M
$187K 0.02%
+19,467
New +$526K
LUNRW
173
DELISTED
Intuitive Machines, Inc. Warrants
LUNRW
$185K 0.02%
922,980
+885,083
+2,335% +$220K
ASAQ.WS
174
DELISTED
Atlantic Avenue Acquisition Corp Warrants, each whole warrant exercisable for one share of Class A common stock at an exercise price of $11.50 per share
ASAQ.WS
$170K 0.02%
2,113,266
+598,098
+39% +$58.3K
AUROW
175
Aurora Innovation Warrant
AUROW
$335M
$168K 0.02%
+357,480
New +$155K

Similar funds

Cowen and Company's Q3 2022 Portfolio in Review

As of Q3 2022, Cowen and Company held 874 positions worth $1.05B, up 0.95% from $1.04B the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Cowen and Company deployed $95.1M of net new capital in Q3 2022, opening 223 new positions and adding to 214 existing holdings. Its largest new stake was iShares iBoxx $ High Yield Corporate Bond ETF: 726,608 shares worth $20.8M.

By sector, the portfolio is most concentrated in Healthcare at 34% of assets, up from 29% a quarter earlier, followed by Financials and Materials.

On the sell side, the largest reduction was Relmada Therapeutics, an estimated $23.6M trimmed.

  • Cowen and Company's largest Q3 2022 buy was iShares iBoxx $ High Yield Corporate Bond ETF: 726,608 shares worth $20.8M.
  • Cowen and Company added most to ARK Innovation ETF in Q3 2022, an estimated $41.6M increase.
  • Cowen and Company's biggest Q3 2022 reduction was Relmada Therapeutics, cutting an estimated $23.6M.
  • Cowen and Company fully exited Pershing Square Tontine Holdings, Ltd. in Q3 2022, selling an estimated $19M.
  • Cowen and Company's ten largest holdings make up 50% of its $1.05B portfolio in Q3 2022.
  • Cowen and Company opened 223 new positions and closed 220 in Q3 2022.
  • Cowen and Company's portfolio value rose 0.95% quarter-over-quarter to $1.05B.

Based on Cowen and Company's 13F filing for Q3 2022, filed 14 Nov 2022.